Paul N. Maton

PAUL N. MATON, MDDigestive Diseases Research Institute, Oklahoma City, Okla.

"These studies add even more support to the body of clinical and scientific knowledge that supports the use of NEXIUM as a generally well-tolerated and efficacious therapy for erosive esophagitis," said Paul N. Maton, MD, principal investigator of a study published in Drug Safety and director of the Digestive Diseases Research Institute in Oklahoma City, Oklahoma.

Dr. Maton's study, reported in Drug Safety (2001; 24(8):625-635), evaluated safety and tolerability of open-label, long-term treatment with esomeprazole in patients with healed erosive esophagitis, and the efficacy in the maintenance of healing over 12 months.

Diarrhea, abdominal pain, flatulence and headache were the only treatment-related adverse events reported by greater than 3 percent of patients.Plasma gastrin levels increased as expected and reached a plateau after three months.In addition, evaluation of gastric biopsies revealed an overall decline in chronic inflammation and atrophy, and intestinal metaplasia findings remained essentially unchanged.

"These studies add even more support to the body of clinical and scientific knowledge that supports the use of NEXIUM as a generally well-tolerated and efficacious therapy for erosive esophagitis," said Paul N. Maton, MD, principal investigator of a study published in Drug Safety and director of the Digestive Diseases Research Institute in Oklahoma City, Oklahoma.

Dr. Maton's study, reported in Drug Safety (2001; 24(8):625-635), evaluated safety and tolerability of open-label, long-term treatment with esomeprazole in patients with healed erosive esophagitis, and the efficacy in the maintenance of healing over 12 months.

Diarrhea, abdominal pain, flatulence and headache were the only treatment-related adverse events reported by greater than 3 percent of patients.Plasma gastrin levels increased as expected and reached a plateau after three months.In addition, evaluation of gastric biopsies revealed an overall decline in chronic inflammation and atrophy, and intestinal metaplasia findings remained essentially unchanged.

"These studies add even more support to the body of clinical and scientific knowledge that supports the use of NEXIUM as a generally well-tolerated and efficacious therapy for erosive esophagitis," said Paul N. Maton, MD, principal investigator of a study published in Drug Safety and director of the Digestive Diseases Research Institute in Oklahoma City, Oklahoma.

Dr. Maton's study, reported in Drug Safety (2001; 24(8):625-635), evaluated safety and tolerability of open-label, long-term treatment with esomeprazole in patients with healed erosive esophagitis, and the efficacy in the maintenance of healing over 12 months.

Diarrhea, abdominal pain, flatulence and headache were the only treatment-related adverse events reported by greater than 3 percent of patients.Plasma gastrin levels increased as expected and reached a plateau after three months.In addition, evaluation of gastric biopsies revealed an overall decline in chronic inflammation and atrophy, and intestinal metaplasia findings remained essentially unchanged.

``These studies add even more support to the body of clinical and scientific knowledge that supports the use of NEXIUM as a generally well-tolerated and efficacious therapy for erosive esophagitis,'' said Paul N. Maton, MD, principal investigator of a study published in Drug Safety and director of the Digestive Diseases Research Institute in Oklahoma City, Oklahoma.

Dr. Maton's study, reported in Drug Safety (2001; 24(8):625-635), evaluated safety and tolerability of open-label, long-term treatment with esomeprazole in patients with healed erosive esophagitis, and the efficacy in the maintenance of healing over 12 months.

Diarrhea, abdominal pain, flatulence and headache were the only treatment-related adverse events reported by greater than 3 percent of patients.Plasma gastrin levels increased as expected and reached a plateau after three months.In addition, evaluation of gastric biopsies revealed an overall decline in chronic inflammation and atrophy, and intestinal metaplasia findings remained essentially unchanged.

Paul N. Maton , MDMedical DirectorOklahoma Foundation for Digestive DiseasesOklahoma City , Oklahoma

Paul N. Maton, MDMedical DirectorOklahoma Foundation for Digestive Diseases

Paul N. Maton, MDMedical DirectorOklahoma Foundation for Digestive Diseases